Arcellx price target raised to $115 from $91 at Piper Sandler
Piper Sandler raised the firm’s price target on Arcellx (ACLX) to $115 from $91 and keeps an Overweight rating on the shares following Q3 ...
Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year?
Based on the latest available data, ACLX has gained about 78.7% so far this year. Meanwhile, the Medical sector has returned an average of 4% on a year-to-date basis. This means that Arcellx, Inc. is ...
Hosted on MSN7h
Gilead Sciences, Inc. (NASDAQ:GILD) Q3 2024 Earnings Call Transcript
The median progression-free survival and overall survival had not yet been reached. Additionally, Arcellx announced yesterday that updated data from the Phase 1 study will be presented at ASH. In the ...
Arcellx Inc’s Promising Clinical Data and Safety Profile Drive Buy Rating
TD Cowen analyst Tyler Van Buren has maintained their bullish stance on ACLX stock, giving a Buy rating on November 6. Tyler Van Buren has ...
Arcellx (NASDAQ:ACLX) Given New $106.00 Price Target at Morgan Stanley
Arcellx (NASDAQ:ACLX – Get Free Report) had its price target increased by Morgan Stanley from $81.00 to $106.00 in a research ...
Zacks.com on MSN22h
Arcellx, Inc. (ACLX) Reports Q3 Loss, Lags Revenue Estimates
Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.81 per share a year ago. These figures are ...
Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today ...